VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. 

Biotechnology

VantAI

VantAI's headquarters in New York, NY, United States

Zachary Carpenter

Adriana Altomonte-Cinotti

Jaewon Kim

Younseop Chung

Zeenat Patrawala

Michael Bronstein

Luca Naef

Bruno Correia

Philippe Schwaller

Head Of Platform

Description

People (14)

Luca Naef

Si-Han Chen

Daniel Kovtun

Chalada Suebsuwong

Thomas Gilgenast

Yusuf Adeshina

Alex Goncearenco

Vivian Lam

Manav Kumar

Andrew Gregory Tsesis

Xuejin Zhang

Michael Finlayson

Jack Kabrich

Younseop Chung

Jobs (1)

Head Of Platform